Male rats treated with either budesonide, prednisolone, or triamcinolone acetonide in drinking water for up to 104 weeks developed slightly increased incidences of basophilic foci, and significantly increased incidences of combined hepatocellular adenomas/carcinomas as compared to controls. Based upon reduced body weight gains and survivals, the doses administered were considered to be toxic. It was concluded that the positive findings represented a class effect, and probably involved glucocorticoid receptors.
Glucocorticoids have not previously been shown to be carcinogenic in animals. This report briefly summarizes positive hepatocarcinogenicity findings in male rats following 2-yr oral administration of 3 different glucocorticoids.
As part of a toxicity testing program for budesonide, a synthetic glucocorticoid, 2-yr carcinogenicity studies were conducted in CD-1 mice and SD rats (Fig. 1 ). No positive findings occurred in mice, but an equivocal increase in liver tumors occurred in male SD rats. A second 2-yr study with larger groups of animals was, therefore, conducted in male rats to assess potential hepatocarcinogenicity. Prednisolone and triamcinolone acetonide were also tested as reference glucocorticoids. The 3 drugs were given in drinking water at equipotent doses as determined by effects on body weight in a 90-daysubchronic study.
Stock dosing solutions were prepared for each test material. Target concentrations for budesonide, prednisolone, and triamcinolone acetonide were 5, 40, and 1.5 wglml, respectively. The appropriate amount of each test material was mixed with 10.0 ml of ethanol and the resultant solutions were added to 20.0 L of tap water. Dosing solutions for each test material were prepared by diluting the stock solutions with tap water as appropriate, based on the most recently available body weight and water consumption data. All dosing solutions were prepared fresh twice weekly, stored at 5-8°C, and water bottles were filled daily. Final ethanol concentrations were 0.005%. Rats in the control groups received ethanolic solution at a concentration equivalent to that for budesonide treated rats. HPLC analysis (column C 18 u Bondapak and 45% ethanol/55% water as mobile phase, flow rate 1 ml/ min; UV-detection at 254 nm) of stock and dosing solutions were performed during the study and found to be within ± 10% of target. The stability of the drugs in the water solutions was also checked and found adequate with virtually no degradation during the actual storage conditions. Male rats (SD rats, Crl: CD-BR, Charles River Laboratories, Kingston, NY) were approximately 7-weeks-old at randomization with a mean body weight of 180 ± 9 g. Rats were housed individually in suspended stainless steel cages, and provided Purina Rodent Laboratory Chow 5001, and tap water ad libitum. Animal room temperature ranged from 20-23°C and the humidity from 30-62%. A controlled diurnal cycle (12-hr-light/12-hr-dark) was maintained. There were 100 animals per group and daily doses administered were as follows: budesonide 50 ~glkg, prednisolone 400 Ag/kg and triamcinolone acetonide 15 ~glkg (all steroids supplied by AB Draco, Sweden). The triamcinolone acetonide dose level was reduced to 10 /ig/kg at the beginning of week 10 and to 5 wg/kg at the beginning of week 21 in order to achieve a reduction in body weight gain similar to that ofbudesonide and prednisolone.
Two control groups were also included with 100 rats per group.
Water consumption was similar among all groups. The average daily compound consumptions during the study were as follows: budesonide, 46.6 (± 3.4) ,ug/kg, weeks 1-104; prednisolone, 368 ( + 26) Ag/kg, weeks 1-104; triamcinolone acetonide, 12.7 (± 1.2) ¡.tg/kg, weeks 1-9; 9.2 (±0.4) ¡.tg/kg, weeks 10-20, and 4.8 (±0.25) 4g/kg, weeks 21-104. The study was performed at Hazleton Laboratories America (Vienna, Virginia) and according to GLP-requirements.
Moribund animals and those surviving until terminal sacrifice ( 104 weeks) were anesthetized with pentobarbital and exsanguinated for necropsy.
Complete necropsies were performed on all animals that died or were sacrificed. All tissues were fixed in 10% neutral buffered formalin. Three liver lobes, plus gross liver lesions, were sectioned at 6 microns and stained with hematoxylin and eosin. Histopathological evaluation was limited to livers and performed by one of us (R.A.S.) without knowledge of experimental group. Proliferative lesions were classified according to the recommendations of Maronpot et al (5) . They were also graded, i.e., ranked semi-quantitatively according to severity, as follows : 1 = slight; 2 = slight to moderate; 3 = moderate ; 4 = moderate to severe; and 5 = severe. For foci and adenomas, the grade was based upon lesion size and number, i.e., the relative amount of liver affected. In the case of carcinomas, the grade was based upon the degree of cellular or histologic atypia as well as tumor size.
Statistical analysis was performed using the onesided Fischer exact test, and not adjusted for survival. Test groups were compared to combined control groups.
A 10% or greater reduction in mean body weights occurred in all drug-treated groups as compared to controls. Survival was also reduced in treated groups (at 104 weeks: controls, 68% and 70%; triamcinolone acetonide, 59%; prednisolone, 53%; and budesonide, 47%).
The incidences and grades of hepatocellular basophilic foci were slightly increased in the drugtreated groups, while there were no apparent effects on eosinophilic foci (Table I) . Some ofthe basophilic foci in treated animals were of the diffuse or atypical type recently described by Harada et al (3) . In diffuse basophilic foci, hepatocytes were enlarged with vesiculate nuclei and diffusely basophilic cytoplasms.
The incidences of hepatocellular adenomas and combined adenomas/carcinomas were significantly increased in all treated groups, with the highest total number of tumors occurring in the prednisolone group (Table II) . The incidence of hepatocellular carcinomas only was not significantly increased, and no effects upon tumor grades were evident. Other histologic findings in the drug-treated groups were striking reductions in portal inflammation and bile duct proliferation, both of which were prevalent in the control groups. Although there was no clear histologic evidence of hepatocytotoxicity, effects on body weight and survival indicate the doses administered were toxic. Moreover, no interim sacrifices or specific studies for hepatotoxicity were conducted. It was concluded that under the conditions of this study, budesonide, prednisolone, and triamcinolone acetonide were tumorigenic in male rat livers.
Results from a battery of in vitro and in vivo tests for genotoxicity tests with budesonide were negative, and glucocorticoids have generally been negative in such studies. The positive results with all 3 glucocorticoids suggest that the findings represent a class effect and probably involve glucocorticoid receptors. Glucocorticoids and sex steroids have previously been reported to be liver tumor promoters in rats, and sex steroids are recognized hepatocarcinogens in humans (1, 2, 4, 6) .
